Robert E. Déziel
Profile
Robert E.
Déziel has been Vice President of Medicinal Chemistry for MethylGene, Inc. since joining the company in 2003.
He was Senior Director of Research for Neokimia, Inc. and Origenix Technologies, Inc. Dr. Déziel had over 18 years of experience in drug discovery at Boehringer Ingelheim and Bristol-Myers Squibb.
He received a PhD in Organic Chemistry from the University of Montreal.
Former positions of Robert E. Déziel
| Companies | Position | End |
|---|---|---|
| Neokimia, Inc. | Chief Tech/Sci/R&D Officer | - |
| Origenix Technologies, Inc. | Chief Tech/Sci/R&D Officer | - |
| MIRATI THERAPEUTICS | Corporate Officer/Principal | - |
Training of Robert E. Déziel
| University of Montréal | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 3 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
| Neokimia, Inc. | Health Technology |
| Origenix Technologies, Inc. |
- Stock Market
- Insiders
- Robert E. Déziel
